Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4527-E4529. doi: 10.1073/pnas.1705234114. Epub 2017 May 16.

Hirofumi Ohashi^{1

2}, Yoshiki Koizumi³, Kento Fukano^{1

4}, Takaji Wakita¹, Alan S Perelson⁵, Shingo Iwami^{6

7

8}, Koichi Watashi^{9

2

8}

¹ Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
² Department of Applied Biological Sciences, Tokyo University of Science, Noda 278-8510, Japan.
³ School of Medicine, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa 920-8640, Japan.
⁴ Department of Analytical Biochemistry, Meiji Pharmaceutical University, Kiyose 204-8588, Japan.
⁵ Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545.
⁶ Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan; siwami@kyushu-u.org kwatashi@nih.go.jp.
⁷ Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency, Saitama 332-0012, Japan.
⁸ Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Saitama 332-0012, Japan.
⁹ Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; siwami@kyushu-u.org kwatashi@nih.go.jp.

No abstract available

Publication types